Table 2.
Group No. | Age, years | 0 day | 14 days a.t. (2 weeks) | 28 days a.t. (4 weeks) | 42 days a.t. (6 weeks) | 56 days a.t. (8 weeks) | 84 days a.t. (12 weeks) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||||
Number of positive samples (percent, %) | EPG counts, average (min-max) | Number of positive samples (percent, %) | EPG counts, average (min-max) | Number of positive samples (percent, %) | EPG counts, average (min-max) | Number of positive samples (percent, %) | EPG counts, average (min-max) | Number of positive samples (percent, %) | EPG counts, average (min-max) | Number of positive samples (percent, %) | EPG counts, average (min-max) | ||
Strongylide therapy | |||||||||||||
1 | 1–10 | 35 (100) | 406.4 (225–850) | 1 (2.9) | 25 | 1 (2.9) | 25 | 2 (5.7) | 37.5 (25–50) | 3 (8.6) | 58.3 (50–75) | 5 (14.3) | 45 (25–75) |
2 | 2–10 | 15 (100) | 485 (250–850) | 6 (40) | 37.5 (25–75) | 0 | 0 | 1 (6.6) | 50 | 3 (20) | 41.6 (25–50) | 9 (66.6) | 63.9 (25–100) |
P. equorum therapy | |||||||||||||
3 | 2–10 | 20 (100) | 276.2 (175–425) | 0 | 0 | 0 | 0 | 0 | 0 | 2 (10) | 25 (25) | 5 (25) | 50 (25–75) |
4 | 1–10 | 40 (100) | 321.7 (175–525) | 1 (2.5) | 25 | 0 | 0 | 2 (5) | 37.5 (25–50) | 2 (5) | 37.5 (25–50) | 25 (62.5) | 66 (25–150) |
5 | 2–3 | 30 (100) | 313.1 (200–550) | 2 (6.6) | 37.5 (25–50) | 0 | 0 | 0 | 0 | 0 | 0 | 17 (56.6) | 69.1 (25–150) |
Days a.t.=Days after therapy.